Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Shares Outstanding (Weighted Average) (2019 - 2025)

Burning Rock Biotech has reported Shares Outstanding (Weighted Average) over the past 7 years, most recently at $2.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.28% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, up 1.28%, while the annual FY2025 figure was $2.4 million, 1.28% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $2.4 million at Burning Rock Biotech, up from $2.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $17.6 million in Q2 2022 and troughed at $2.4 million in Q4 2024.
  • A 5-year average of $8.2 million and a median of $7.3 million in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 349.27% in 2022 and later crashed 79.59% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $2.7 million in 2021, then soared by 349.27% to $12.2 million in 2022, then dropped by 2.95% to $11.8 million in 2023, then crashed by 79.59% to $2.4 million in 2024, then grew by 1.28% to $2.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BNR at $2.4 million in Q4 2025, $2.4 million in Q4 2024, and $11.8 million in Q4 2023.